Xtl Biopharmaceuticals (XTLB) Net Income towards Common Stockholders Growth (5y) (2014 - 2024)
Xtl Biopharmaceuticals (XTLB) Net Income towards Common Stockholders Growth (5y) (2014 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -33.95% |
| Sep 30, 2024 | 1,492.58% |
| Jun 30, 2024 | -932.49% |
| Mar 31, 2024 | 804.75% |
| Dec 31, 2023 | 7.23% |
| Sep 30, 2023 | 1,281.66% |
| Mar 31, 2023 | -1,256.62% |
| Dec 31, 2022 | -135.93% |
| Sep 30, 2022 | -788.11% |
| Jun 30, 2022 | -889.80% |
| Mar 31, 2022 | 651.70% |
| Dec 31, 2021 | -791.30% |
| Sep 30, 2021 | -1,439.58% |
| Jun 30, 2021 | 1,318.84% |
| Mar 31, 2021 | 974.16% |
| Dec 31, 2020 | -14.88% |
| Sep 30, 2020 | -20.11% |
| Jun 30, 2020 | 24.57% |
| Dec 31, 2019 | -14.06% |
| Sep 30, 2019 | -14.87% |